Immunological therapies in lymphoproliferative disorders reviewed.

2004 JUL 7 - (NewsRx.com & NewsRx.net) -- A scientist reviews the accomplishments and perspectives of immunological interventions in lymphoproliferative disorders in a recent issue of the Journal of Experimental and Clinical Cancer Research.

According to a study from Yugoslavia, "The purpose of this review is to consider evidences accumulated in the last few years which might lead to a new therapeutic strategy for lymphoproliferative disorders. Tumor-targeted and immunologically designed therapy has already started. Clinical effectiveness also includes the primary and secondary prevention of these malignancies. The fortifying of body's defense through vaccination as primary prevention with tumor-specific cell surface antigen, has been seen over the past few years, and will lead to health patient's improvement."

"Data collected from clinical trials and in vitro analysis indicated that the immune system of patients could recognize and eliminate neoplastic cells while sparing normal cells," said D. B. Milosevic at the Institute for Oncology & Radiology of Serbia. "In B-cell lymphomas and myelomas, the tumor-idiotype (Id) produced by a single B-cell clone, has been used for vaccination. Therapeutic Id vaccination used two types of antigen-presenting cells as natural adjuvants for the induction of antigen-specific T cell response. Dendritic cell (DC)-based vaccines are under active investigation and are entering clinical evaluation."

"Current research focuses on optimization of DC source, ...